Novo Nordisk’s (NVO) update that the FDA classified Catalent’s facility as “Official Action Indicated” raises the risk of further delay for Regeneron’s (REGN) EYLEA HD prefilled syringe, which is produced at the same site, Canaccord tells investors in a research note. Despite ongoing EYLEA franchise headwinds, the firm maintains a Buy rating and $850 price target on Regeneron, as upcoming data on Novo’s semaglutide in Alzheimer’s disease could spotlight Regeneron’s related muscle-sparing programs. A positive readout could also prompt Regeneron to explore combining trevogrumab and/or garetosmab with a GLP-1 therapy for Alzheimer’s, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $660 from $650 at Citi
- Regeneron announces updated data for DB-OTO due to OTOF gene
- Regeneron and Bayer Complete Long-term Study on Retinopathy of Prematurity Treatments
- Regeneron Completes Study on Aflibercept’s Safety in Real-World Settings
- Regeneron’s Odronextamab Study Update: A Potential Game-Changer in B-Cell Malignancies